VEGFA and neoplasm: Indeed, antiangiogenic therapies (mainly based on the use of monoclonal antibodies against VEGF-A) [35] are administered, independently from evaluation of VEGF-A levels, to promote vessel normalization, a process that – restoring proper tumor perfusion and oxygenation – limits tumor cell invasiveness and improve the effectiveness of anticancer treatments [36–38].